Patents by Inventor Sonja Kriks

Sonja Kriks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12084679
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: September 10, 2024
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stefan Irion, Mark Tomishima, Sonja Kriks
  • Publication number: 20240263134
    Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Application
    Filed: February 29, 2024
    Publication date: August 8, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
  • Patent number: 11970712
    Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: April 30, 2024
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
  • Publication number: 20210123018
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.
    Type: Application
    Filed: November 9, 2020
    Publication date: April 29, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stefan Irion, Mark Tomishima, Sonja Kriks
  • Publication number: 20200407680
    Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 31, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
  • Patent number: 10858625
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 8, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stefan Irion, Mark Tomishima, Sonja Kriks
  • Patent number: 10711243
    Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: July 14, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
  • Publication number: 20190211306
    Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 11, 2019
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
  • Patent number: 10280398
    Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: May 7, 2019
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
  • Publication number: 20180369287
    Abstract: The present invention provides cell populations enriched for specific neural precursor markers and methods of using such cell populations for treatment of disorders associated with dysregulation of inhibitory neuronal function and/or imbalances in excitatory/inhibitory neuronal activity. In particular, the present invention provides cell populations for use as a cell-based therapeutic, and methods for purification and use of these neural precursor cells in transplantation to ameliorate neural disorders associated with aberrant neural function.
    Type: Application
    Filed: October 10, 2016
    Publication date: December 27, 2018
    Inventors: Cory Nicholas, Luis Fuentealba, Cheuk Ka Tong, Marina Bershteyn, Sonja Kriks, Stuart Chambers
  • Publication number: 20180094242
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 5, 2018
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stefan Irion, Mark Tomishima, Sonja Kriks
  • Publication number: 20150010514
    Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Application
    Filed: November 2, 2012
    Publication date: January 8, 2015
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks